Skip to main content

TScan Therapeutics, Inc.

TCRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001783328

No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.

Superinvestors holding TCRX, Q2 2026

See all superinvestors

No superinvestor reported holding TCRX in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of TCRX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q2 2022

    0 superinvestors holding at quarter end

    Sold out
    HHLR Advisors (Hillhouse)
  2. Q1 2022

    1 superinvestor holding at quarter end

    Reduced
    HHLR Advisors (Hillhouse) (−47.8%)
  3. Q3 2021

    1 superinvestor holding at quarter end

    New
    HHLR Advisors (Hillhouse)